Clinical trials: Myosteatosis
Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease
Investigating Myosteatosis in Steatotic Liver Diseases
Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities …
- Conditions
- Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease of Mixed Origin (MetALD), Steatotic Liver Diseases
- Trial name
- MYO-SLD (NCT06514300)
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cirrhosis, Myosteatosis
Protocol for Muscle Attenuation Cut-offs in Cirrhosis
The goal of this observational study is to learn if new muscle attenuation cut-offs for the definition of myosteatosis can better predict survival in patients with cirrhosis.
- Conditions
- Cirrhosis, Myosteatosis, Sarcopenia, Sarcopenia in Liver Cirrhosis
- Trial name
- Myocirrhosis (NCT06593015)
- Testing
- Radiological tool for the diagnosis of myosteatosis
- Where
- Italy
- Volunteers
- 1,296 people
- Sponsor
- University of Roma La Sapienza
Skeletal Muscle Radiodensity, Myosteatosis
Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a 5-year survival rate as low as 6%. It causes body composition changes and many patients develop muscle loss with disease progression.
- Conditions
- Skeletal Muscle Radiodensity, Myosteatosis, Scr/CysC Ratio, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05584852
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The Affiliated Hospital of Qingdao University